Tempus AI leverages AI for treatment decisions and diagnostics, thriving in the booming healthcare AI market with strong ...

Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark ...

Tempus AI's financials have significantly improved, with positive cash flow expected next quarter. Read why TEM stock is a ...

The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus’ genomics capabilities by adding a ...

Acquisition: Closed the acquisition of Ambry Genetics on February 3. Google Agreement: Extended for another five years. Tempus AI Inc (NASDAQ:TEM) reported a 35.8% year-over-year revenue growth in ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ ... of approximately $1.24 billion for the consolidated Tempus and Ambry Genetics business, which represents approximately 79% annual growth ...

Despite filing a fourth-quarter and year-end 2024 earnings report that the CEO described as "fantastic" yesterday afternoon, Tempus AI shares fell overnight and a major investment house downgraded ...